Epinephrine Dose: Optimal Versus Standard Evaluation Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,790

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Cardiac Arrest, Out-Of-HospitalSudden Cardiac ArrestVentricular FibrillationVentricular Tachycardia-Pulseless
Interventions
DRUG

Epinephrine

Epinephrine 1mg 1:10000 (10cc) per dose

Trial Locations (3)

V8W 9P1

RECRUITING

British Columbia Emergency Health Services (BCEHS), Victoria

L6M 3L1

RECRUITING

Halton Region Paramedic Services, Halton

K1H 1E2

RECRUITING

Ottawa Paramedic Services, Ottawa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Pfizer

INDUSTRY

lead

Unity Health Toronto

OTHER

NCT03826524 - Epinephrine Dose: Optimal Versus Standard Evaluation Trial | Biotech Hunter | Biotech Hunter